ArticleGut and liver2013
Chemotherapy for advanced gastric cancer: review and update of current practices.
Article in Gut and liver, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis.Scientific reports · 2017Pooled it
- Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.Technology in cancer research & treatment · 2019Trial
- S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.Oncotarget · 2015Trial
- Targeting the c-Met/VEGFR Pathway to BoostCells · 2026Article
- PICK1 modulates the proliferation and migration of gastric cancer cells by regulating TLR4.Journal of Zhejiang University. Science. B · 2025Article
- Prognostic factors and the role of chemotherapy in patients with pT3N0M0 gastric cancer: a propensity score matching analysis based on the SEER database.Discover oncology · 2025Article
- Emerging role of circular RNAs in gastric cancer: From basic biology to clinical applications (Review).Molecular medicine reports · 2025Review
- Efficacy and Safety of mFOLFOX-6 in Advanced Gastric Cancer: A Prospective Observational Study.South Asian journal of cancer · 2025Article
- ZNF521/EBF1 axis regulates AKR1B1 to promote the proliferation, migration, and invasion of gastric cancer cells.The Kaohsiung journal of medical sciences · 2023Article
- Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer.Journal of education and health promotion · 2023Article
- A combined analysis of bulk and single-cell sequencing data reveals that depleted extracellular matrix and enhanced immune processes co-contribute to fluorouracil beneficial responses in gastric cancer.Frontiers in immunology · 2022Article
- Survival outcomes of management in metastatic gastric adenocarcinoma patients.Scientific reports · 2021Article
- Patient-reported symptoms in metastatic gastric cancer patients in the last 6 months of life.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Release of a liver anticancer drug, sorafenib from its PVA/LDH- and PEG/LDH-coated iron oxide nanoparticles for drug delivery applications.Scientific reports · 2020Article
- Stent-in-Stent for Malign Obstruction: Should We Go Back to a Place Where We Were Happy?GE Portuguese journal of gastroenterology · 2020Article
- DHA Abolishes the Detrimental Effect of Docetaxel on Downregulation of the MICA via Decreasing the Expression Level of MicroRNA-20a in Gastric Cancer.Journal of gastrointestinal cancer · 2020Article
- Article
- Association of serum levels of deoxyribose 1-phosphate and S-lactoylglutathione with neoadjuvant chemotherapy sensitivity in patients with gastric cancer: A metabolomics study.Oncology letters · 2020Article
- Article
- Ki-67 labeling index as a prognostic marker in advanced stomach cancer.Annals of surgical treatment and research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No standard adjuvant or palliative chemotherapy regimen has been internationally approved for patients with advanced gastric cancer. Adjuvant chemoradiotherapy is administered prior to surgery and is used in the Unitied States, and intensified chemotherapy is administered prior to and after surgery and is used in Europe. Limited D1 dissections are also frequently performed in the United States and Europe. In Korea, patients undergoing D2 resection appear to benefit from postoperative adjuvant chemotherapy using S-1 or capecitabine plus oxaliplatin. Fluoropyrimidine, platinum, taxane, epirubicin, and irinotecan may be employed alone or in combination as a first-line therapy in a palliative chemotherapy regimen. In Asia, an orally administered fluoropyrimidine, such as capecitabine or S-1, is favored over the continuous infusion of 5-fluorouracil because of its convenience. Trastuzumab has been integrated into the current standard chemotherapy for human epidermal growth factor receptor 2-overexpressing gastric cancers. There is currently no standard regimen for secondary palliative chemotherapy. Clinical studies of several targeted therapies are ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.